Pakistan's pharma sector objects to MFN status to India

Pak is apprehensive that if it allows pharma products import from India, local producers' livelihood might get impacted

After its influential agriculture lobby, pharmaceutical industry associations in have now put their foot down against granting the most-favoured nation (MFN) status to India.

is apprehensive that if it allows the import of pharmaceutical products from India, local producers’ livelihood might get hampered. The pharmaceutical trade has huge potential for India. The pharmaceutical industry in is at a nascent stage and is highly unorganised. So, their fear is natural,” a senior official told Business Standard.

Some associations in have also complained that India does not follow the necessary drug regulation policies as prescribed by the World Health Organization (WHO). According to one official, his country will allow the import of only those drugs from India that are approved by the European Pharmacopoeia.

A recent study by Assocham said pharmaceutical trade between India and is likely to emerge as one of the potential sectors after status is granted to India. The pharmaceutical industry in is in the process of being organised and is expanding its wings across the country. Compared to India’s pharmaceutical industry, the size of local producers in is quite small.

India is the third largest producer of pharmaceutical products in the world in terms of volume, and its domestic pharmaceutical industry is expected to reach $55 billion by 2020 from $12.26 billion as of 2009. Further, foreign markets of Indian pharmaceutical products are likely to increase to $70 billion by 2020, Assocham stated.

In an effort to liberalise trade and business relations with India, for the first time ever had issued a negative list of items that India cannot export to Pakistan. The list, which became operational from March last year, contained 1,209 items.

Interestingly, while claimed that it had trimmed the negative list of items, throwing open more than 7,000 products that India can export to Pakistan, it put all the items of India’s interest in the negative list in a clandestine manner. Some of those items are agricultural products, chemicals and pharmaceutical products.

Under the pharmaceuticals products category, as many as 49 items have been kept under the list of banned items. Some of the items that are banned include Ibuprofen, Paracetamol, Penicillin, Ampicillin, antibiotics containing insulin, eye drops, ointments and vaccines for veterinary medicine among others.

Once status is granted to India, even the negative list is expected to be phased out.

image
Business Standard
177 22
Business Standard

Pakistan's pharma sector objects to MFN status to India

Pak is apprehensive that if it allows pharma products import from India, local producers' livelihood might get impacted

Nayanima Basu  |  New Delhi 

After its influential agriculture lobby, pharmaceutical industry associations in have now put their foot down against granting the most-favoured nation (MFN) status to India.

is apprehensive that if it allows the import of pharmaceutical products from India, local producers’ livelihood might get hampered. The pharmaceutical trade has huge potential for India. The pharmaceutical industry in is at a nascent stage and is highly unorganised. So, their fear is natural,” a senior official told Business Standard.



Some associations in have also complained that India does not follow the necessary drug regulation policies as prescribed by the World Health Organization (WHO). According to one official, his country will allow the import of only those drugs from India that are approved by the European Pharmacopoeia.

A recent study by Assocham said pharmaceutical trade between India and is likely to emerge as one of the potential sectors after status is granted to India. The pharmaceutical industry in is in the process of being organised and is expanding its wings across the country. Compared to India’s pharmaceutical industry, the size of local producers in is quite small.

India is the third largest producer of pharmaceutical products in the world in terms of volume, and its domestic pharmaceutical industry is expected to reach $55 billion by 2020 from $12.26 billion as of 2009. Further, foreign markets of Indian pharmaceutical products are likely to increase to $70 billion by 2020, Assocham stated.

In an effort to liberalise trade and business relations with India, for the first time ever had issued a negative list of items that India cannot export to Pakistan. The list, which became operational from March last year, contained 1,209 items.

Interestingly, while claimed that it had trimmed the negative list of items, throwing open more than 7,000 products that India can export to Pakistan, it put all the items of India’s interest in the negative list in a clandestine manner. Some of those items are agricultural products, chemicals and pharmaceutical products.

Under the pharmaceuticals products category, as many as 49 items have been kept under the list of banned items. Some of the items that are banned include Ibuprofen, Paracetamol, Penicillin, Ampicillin, antibiotics containing insulin, eye drops, ointments and vaccines for veterinary medicine among others.

Once status is granted to India, even the negative list is expected to be phased out.

RECOMMENDED FOR YOU

Pakistan's pharma sector objects to MFN status to India

Pak is apprehensive that if it allows pharma products import from India, local producers' livelihood might get impacted

Pak is apprehensive that if it allows pharma products import from India, local producers' livelihood might get impacted After its influential agriculture lobby, pharmaceutical industry associations in have now put their foot down against granting the most-favoured nation (MFN) status to India.

is apprehensive that if it allows the import of pharmaceutical products from India, local producers’ livelihood might get hampered. The pharmaceutical trade has huge potential for India. The pharmaceutical industry in is at a nascent stage and is highly unorganised. So, their fear is natural,” a senior official told Business Standard.

Some associations in have also complained that India does not follow the necessary drug regulation policies as prescribed by the World Health Organization (WHO). According to one official, his country will allow the import of only those drugs from India that are approved by the European Pharmacopoeia.

A recent study by Assocham said pharmaceutical trade between India and is likely to emerge as one of the potential sectors after status is granted to India. The pharmaceutical industry in is in the process of being organised and is expanding its wings across the country. Compared to India’s pharmaceutical industry, the size of local producers in is quite small.

India is the third largest producer of pharmaceutical products in the world in terms of volume, and its domestic pharmaceutical industry is expected to reach $55 billion by 2020 from $12.26 billion as of 2009. Further, foreign markets of Indian pharmaceutical products are likely to increase to $70 billion by 2020, Assocham stated.

In an effort to liberalise trade and business relations with India, for the first time ever had issued a negative list of items that India cannot export to Pakistan. The list, which became operational from March last year, contained 1,209 items.

Interestingly, while claimed that it had trimmed the negative list of items, throwing open more than 7,000 products that India can export to Pakistan, it put all the items of India’s interest in the negative list in a clandestine manner. Some of those items are agricultural products, chemicals and pharmaceutical products.

Under the pharmaceuticals products category, as many as 49 items have been kept under the list of banned items. Some of the items that are banned include Ibuprofen, Paracetamol, Penicillin, Ampicillin, antibiotics containing insulin, eye drops, ointments and vaccines for veterinary medicine among others.

Once status is granted to India, even the negative list is expected to be phased out.
image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard